These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37938423)

  • 1. CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms.
    Wang Y; Wen J; Sun X; Sun Y; Liu Y; Cheng X; Wu W; Liu Q; Ren F
    Cancer Chemother Pharmacol; 2024 Apr; 93(4):295-306. PubMed ID: 37938423
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
    Fu XH; Zhang X; Yang H; Xu XW; Hu ZL; Yan J; Zheng XL; Wei RR; Zhang ZQ; Tang SR; Geng MY; Huang X
    Acta Pharmacol Sin; 2019 May; 40(5):677-688. PubMed ID: 30224636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor activity and mechanism of resistance of the novel HDAC and PI3K dual inhibitor CUDC-907 in pancreatic cancer.
    Liu S; Zhao S; Dong Y; Wang T; Niu X; Zhao L; Wang G
    Cancer Chemother Pharmacol; 2021 Mar; 87(3):415-423. PubMed ID: 33392641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
    Hu C; Xia H; Bai S; Zhao J; Edwards H; Li X; Yang Y; Lyu J; Wang G; Zhan Y; Dong Y; Ge Y
    J Cell Mol Med; 2020 Jul; 24(13):7239-7253. PubMed ID: 32459381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
    Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
    Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual Inhibition of HDAC and Tyrosine Kinase Signaling Pathways with CUDC-907 Inhibits Thyroid Cancer Growth and Metastases.
    Kotian S; Zhang L; Boufraqech M; Gaskins K; Gara SK; Quezado M; Nilubol N; Kebebew E
    Clin Cancer Res; 2017 Sep; 23(17):5044-5054. PubMed ID: 28600475
    [No Abstract]   [Full Text] [Related]  

  • 8. Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.
    Mondello P; Derenzini E; Asgari Z; Philip J; Brea EJ; Seshan V; Hendrickson RC; de Stanchina E; Scheinberg DA; Younes A
    Oncotarget; 2017 Feb; 8(8):14017-14028. PubMed ID: 28147336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
    Jung M; Kim S; Lee JK; Yoon SO; Park HS; Hong SW; Park WS; Kim JE; Kim J; Keam B; Kim HJ; Kang HJ; Kim DW; Jung KC; Kim YT; Heo DS; Kim TM; Jeon YK
    Oncologist; 2019 Aug; 24(8):e740-e748. PubMed ID: 30696721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase.
    Wu CP; Hsieh YJ; Hsiao SH; Su CY; Li YQ; Huang YH; Huang CW; Hsieh CH; Yu JS; Wu YS
    Mol Pharm; 2016 Mar; 13(3):784-94. PubMed ID: 26796063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 attenuates TGFβ1 induced lung and tumor fibrosis.
    Zhang W; Zhang Y; Tu T; Schmull S; Han Y; Wang W; Li H
    Cell Death Dis; 2020 Sep; 11(9):765. PubMed ID: 32943605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of CUDC-907, a dual phosphoinositide-3 kinase and histone deacetylase inhibitor, in inhibiting proliferation of adult T-cell leukemia.
    Ishikawa C; Mori N
    Eur J Haematol; 2020 Dec; 105(6):763-772. PubMed ID: 32780889
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CUDC-907, a dual HDAC and PI3K inhibitor, reverses platinum drug resistance.
    To KKW; Fu LW
    Invest New Drugs; 2018 Feb; 36(1):10-19. PubMed ID: 28819699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.
    Li X; Su Y; Madlambayan G; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Ma J; Knight T; Wang G; Wang Y; Yang J; Taub JW; Lin H; Ge Y
    Haematologica; 2019 Nov; 104(11):2225-2240. PubMed ID: 30819918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
    Sun K; Atoyan R; Borek MA; Dellarocca S; Samson ME; Ma AW; Xu GX; Patterson T; Tuck DP; Viner JL; Fattaey A; Wang J
    Mol Cancer Ther; 2017 Feb; 16(2):285-299. PubMed ID: 27980108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CUDC-101 as a dual-target inhibitor of EGFR and HDAC enhances the anti-myeloma effects of bortezomib by regulating G2/M cell cycle arrest.
    Cao W; Yao S; Li A; Chen H; Zhang E; Cao L; Zhang J; Hou Y; Dai Z; Chen J; Huang X; Yang L; Cai Z
    J Zhejiang Univ Sci B; 2023 May; 24(5):442-454. PubMed ID: 37190893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Corticotroph HDAC and PI3-Kinase in Cushing Disease.
    Zhang D; Damoiseaux R; Babayan L; Rivera-Meza EK; Yang Y; Bergsneider M; Wang MB; Yong WH; Kelly K; Heaney AP
    J Clin Endocrinol Metab; 2021 Jan; 106(1):e232-e246. PubMed ID: 33000123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Root extract of Hemsleya amabilis Diels suppresses renal cell carcinoma cell growth through inducing apoptosis and G
    Li K; You G; Jiang K; Wang R; Li W; Meng Y; Fang Y; Chen W; Zhu G; Song J; Wang W; Su H; Hu B; Sun F; Jia Z; Li C; Zhu J
    J Ethnopharmacol; 2024 Jan; 318(Pt B):117014. PubMed ID: 37557938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia.
    Li X; Su Y; Hege K; Madlambayan G; Edwards H; Knight T; Polin L; Kushner J; Dzinic SH; White K; Yang J; Miller R; Wang G; Zhao L; Wang Y; Lin H; Taub JW; Ge Y
    Haematologica; 2021 May; 106(5):1262-1277. PubMed ID: 32165486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The anti-tumor effect of OP-B on ovarian cancer in vitro and in vivo, and its mechanism: An investigation using network pharmacology-based analysis.
    Yuan S; Xu Y; Yi T; Wang H
    J Ethnopharmacol; 2022 Jan; 283():114706. PubMed ID: 34614446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.